The adjusted risk ratio for pneumocystosis was 0.63 (95% CI, 0.03, 14.89; P = 0.77) when the risk of these patients compared to that of the patients who discontinued primary or secondary prophylaxis after CD4 counts increased to ≧200 cells/μL. The gene discussed is CD4; the disease is pneumocystosis.